



IBA Submits the Filing of the New Imaging Software Platform, adaPT insight*

IBA presents its novel imaging software platform that is part of IBA's adaPT Treatment Suite

Louvain-la-Neuve, Belgium September 22nd, 2013 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has submitted all necessary documentation on IBA's new imaging software platform to the U.S. Food and Drug Administration (FDA) for Marketing Authorization.

IBA is proud to complement its proton therapy offering with a brand new imaging platform, adaPT Insight*. AdaPT Insight* is part of IBA's integrated proton therapy software suite, adaPT Treatment Suite. It incorporates image-guidance features such as 3D Cone Beam CT** and stereoscopic X-Ray imaging for increased accuracy in patient treatments. An open architecture and programmable workflow configurability builds a solid foundation for the development of future specific image-guided proton therapy (IGPT) solutions.

AdaPT Treatment Suite is proposing a truly integrated treatment environment for safe and efficient proton therapy delivery, including three major software platforms. Besides the brand new imaging platform, IBA's adaPT Treatment Suite integrates adaPT Deliver and adaPT Prescribe.

AdaPT Deliver is the front-end of the treatment delivery. It incorporates the different delivery techniques, such as Pencil Beam Scanning, and it offers ergonomic screens for streamlined control of the patient treatment, along with full integration of the TPS and OIS through DICOM connectivity.

AdaPT Prescribe allows editing of treatment plans and prescriptions for standalone or QA modes.

David Wikler, Product Development Manager at IBA commented: "Specific applications of image-guidance and image-monitoring are of paramount importance to benefit from the protons superior dose distribution. Thanks to our strong imaging group, successful



collaborations (especially with University of Louvain-la-Neuve) and the new imaging platform that we developed, we have built the foundation enabling the installation of Proton Therapy specific Cone Beam CT** and the translation of our imaging research programs into clinical products.”

**adaPT Insight is the brand name of the I2C software file which is submitted to the FDA for market approval and will be subject to review by competent authorities (FDA, Notified bodies, et al...).*

***CBCT is an ongoing development. The marketing approval will be subject to review by competent authorities (FDA, Notified bodies, et al...).*

-ENDS-

Notes to Editors

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced side effects. Protons deposit the majority of their effective energy within a precisely controlled range within a tumour, sparing healthy surrounding tissue. Higher doses can be delivered to the tumour without increasing the risk of side effects and long-term complications, improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide utilize IBA solutions. This includes 15 proton therapy centres in operation and 11 centres under development. Over 25,000 patients have been treated on IBA equipment – more than all competitor installations combined.

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company’s primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA’s proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.



Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager PT
+32 10 475 890
Investorrelations@iba-group.com